Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: A randomized, controlled trial

M. Boogaerts, D. J. Winston, E. J. Bow, G. Garber, A. C. Reboli, A. P. Schwarer, N. Novitzky, A. Boehme, E. Chwetzoff, K. De Beule, C. Arthur, K. Lechner, W. Linkesch, R. Waldner, A. Bosly, F. Crokaert, J. Maertens, J. Michaux, L. Noens, W. SchroyensA. Van Hoof, I. Fong, A. Keating, M. Laverdière, A. McGeer, S. Nantel, C. Rotstein, W. Schlech, F. Smaill, P. Cassassus, P. Fenaux, S. Francois, R. Herbrecht, N. Ifrah, J. Pris, C. Mounier, G. Nedellec, P. Oriol, C. Rieux, A. Stamatoullas, J. Vernant, B. Witz, H. Goldschmidt, M. Pfreundschuh, U. Schuler, S. Daenen, A. Dekker, M. Kramer, M. Van Marwijk Kooy, E. Blundell, D. Milligan, G. Morgenstern, A. Pagliuca, H. Prentice, S. Rule, S. Schey, E. Anaissie, P. Arnow, J. Blummer, M. Martin, M. Territo, J. Wingard, T. Burzykowski, G. Molenberghs, A. Cuijpers, I. Van Hoof, C. Vertommen

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

344 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: A randomized, controlled trial'. En conjunto forman una huella única.

Medicine & Life Sciences